Meeting
2022 ASCO Annual Meeting
Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.
Authors
Chris Labaki
Dana Farber Cancer Institute, Boston, MA
Chris Labaki , Ziad Bakouny , Thibaut Sanglier , Andrew Lachlan Schmidt , Jinjoo Shim , David A. Braun , Fanny Bouquet , Wanling Xie , Sara M. Tolaney , Toni K. Choueiri , Maureen Ann Joyce
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Real-World Data/Outcomes
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6520)
DOI
10.1200/JCO.2022.40.16_suppl.6520
Abstract #
6520
Poster Bd #
303
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Clinical outcome of patients experiencing central nervous system progression on first-line pertuzumab and trastuzumab for HER2-positive metastatic breast cancer in a real-life cohort.
First Author: Laetitia Collet
Poster
2019 ASCO Annual Meeting
Real-world treatment patterns and outcomes in ER+/PR+/HER2+ metastatic breast cancer (MBC) patients: A National Cancer Database analysis.
First Author: Abby Statler
Poster
2023 ASCO Quality Care Symposium
Real-world overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic therapy (tx): Results from IMPACT UC II.
First Author: Mehmet Asim Bilen
Poster
2023 ASCO Annual Meeting
Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.
First Author: Joseph J Zhao